Avalo Therapeutics Enters Material Agreement and Reports First-Quarter Financial Results

Avalo Therapeutics Inc. (AVTX) entered a material definitive agreement and furnished its first-quarter financial results in a Form 8-K filed with the SEC on May 7, 2026.

The filing, submitted under Items 1.01, 2.02, 7.01 and 9.01, covers entry into the agreement, quarterly results, Regulation FD disclosure and related exhibits. Avalo Therapeutics is a clinical-stage biotechnology company whose common stock trades on a national exchange under the ticker AVTX.

The material definitive agreement changes the company's contractual position from its prior state by adding binding obligations with the named counterparty. The contract type and any dollar size are stated in the filing's Item 1.01 exhibit. The new agreement takes effect immediately upon execution on or before the filing date of May 7, 2026.

Item 1.02 is not invoked, so no termination of a prior contract is reported.

Operationally the company must now perform under the new agreement's terms, including any supply, financing or partnership deliverables. Failure to meet contractual milestones can accelerate separate SEC filings or regulatory notifications required under securities law.

The quarterly results under Item 2.02 update the public record on liquidity and operating expenses, data that market participants and creditors rely on for compliance with existing debt covenants or listing standards.

Downstream, the agreement and results disclosure start the clock on any follow-on contractual deliverables, such as payments, data transfers or regulatory submissions referenced in the exhibits. The company must retain the agreement exhibit for SEC review and incorporate the financial information into its next periodic report.

Standard securities rules require prompt amendment if material facts in the furnished information change.

This marks the latest 8-K from Avalo Therapeutics in 2026. The company has previously used Form 8-K to report similar material agreements and quarterly financial updates as required under SEC Regulation FD and Items 1.01 and 2.02. The filing constitutes the primary official record; no other sources were used to compile these facts.